

## **Important Notice and Disclaimer**

This presentation has been prepared by TFS Corporation Ltd ("TFS").

This presentation is not a product disclosure statement or prospectus for the purposes of the Australian *Corporations Act 2001* (Cth), nor does it constitute financial product or investment advice or a recommendation, offer or invitation by any person or to any person to sell, purchase or otherwise invest in securities in TFS in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment.

This presentation contains general information only and does not take into account the investment objectives, financial situation and particular needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser, lawyer, accountant, tax or such other adviser as considered appropriate having regard to their objectives, financial situation and needs before taking any action.

The information in this presentation contains historic information about the performance of TFS and securities in TFS (or any other financial product). That information is historic only, and is not an indication or representation about the future performance of TFS or securities in TFS (or any other financial product). You should not place undue reliance on any such information.

No representation or warranty, express or implied, is given as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty, express or implied, given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or potential returns contained in this presentation. Such forecasts, prospective statements or potential returns only reflect subjective views held by TFS, and are based on certain assumptions made by TFS, as at the date specified in the relevant information and are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of TFS. Actual events and results may vary from the events or results expressed or implied in such statements. Given these uncertainties, you should not place undue reliance on any such statements.

To the maximum extent permitted by law, TFS and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising in negligence, statute or otherwise) for any direct or indirect loss or damage which may arise or be suffered by any person through use or reliance on anything contained in, or omitted from, this presentation.

An investment in TFS securities is subject to investment and other known and unknown risks, some of which are beyond the control of TFS. TFS does not guarantee any particular rate of return or the performance of TFS securities.

The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.



## A Strong Start to FY16


- Multi-year agreements signed with Chinese and Indian wood buyers 100% of TFS owned wood from the 2016 and 2017 harvests is now forward sold, at prices broadly equivalent to US\$4,500 per kg of oil
- Cash EBITDA<sup>1</sup> up 29% on prior year, with guidance<sup>2</sup> reaffirmed
- Annual harvest to commence in May of > 300t of heartwood up tenfold on FY15
- Significant growth in sales of Benzac® royalty receipts tripled in Q2 FY16
- Plantation sales up 50% on prior year with strong demand from all investor groups
- Cash balance of \$52m (compared to \$30m at 31 December 2014)
- Total estate now at 10,583ha with a further 1,500ha of plantings planned for Q4 FY16

<u>Note 1</u> - As in previous years, Cash EBITDA equals EBITDA less the fair value gain on the biological assets, revenue from the recognition of deferred lease and management fees and unrealised foreign exchange movements. In addition, Cash EBITDA excludes the non-cash accounting gain associated with the Group's acquisition of Santalis Pharmaceuticals and Viroxis Corporation in July 2015.

 $\underline{\text{\bf Note 2}}$  - Guidance is for FY16 Cash EBITDA to increase by between 5% and 10% on FY15

TFS Corporation Ltd

## **Key Financial & Operational Results**



FY16 planting of around 1,500ha will commence in April, after the wet season

Note 1 - NPAT includes the fair value gain on TFS's owned biological assets, revenue from the recognition of deferred lease and management fees, unrealised foreign exchange movements and the accounting profit of \$17.2m generated from the Group's acquisition of Santalis Pharmaceuticals and Viroxis Corporation in July 2015

## **Growth in TFS Owned Plantations**



# **Good Progress Against FY16 Priorities**

| Priority   |             | Progress  |
|--|-------------|---|
| Expand operations to harvest > 300t of heartwood   | <b>Ø</b>    | Harvest to commence in May, post wet season<br>Operational expansion (people and equipment) complete<br>Installation of new production line at processing facility        |
| Develop end markets and finalise supply agreements | <b>②</b>    | 100% of TFS owned harvest in 2016 & 2017 is forward sold<br>First supply agreement signed with Chinese wood buyer<br>First supply agreement signed with Indian wood buyer |
| Extend plantation ownership                        | •           | TFS owned estate increased to 3,547ha Finalised plans to buyback plantations from MIS growers   |
| Progress pharmaceutical product development        | •           | Strong Benzac® performance – 1m units shipped in Q2 FY16 Phase 2 trials for <i>oral mucositis</i> & <i>molluscum contagiosum</i>  |
| Introduce new plantation investors                 |             | Strong start to FY16 with sales up 50% in H1 Promising levels of domestic interest  |
| Review refinance of senior secured notes           | <b>&gt;</b> | Notes mature in July 2018 Leading bank appointed & preparatory work complete Early call premium reduces by 50% (US\$8m) in July 2016                                      |




ffs




## **Key Financial Results**


#### Cash Revenue (\$m)




#### Cash EBITDA (\$m)



#### NPAT (\$m)




#### **NTA (\$m)**




6%

NTA reduction due to the acquisition of Santalis and Viroxis, adding intangible assets of \$136m and liabilities (contingent consideration) of \$38m - see slide 33

# Cash EBITDA up by 29%



## **Broadly Based Revenue Growth**







## **Strong Momentum in Sandalwood Product Sales**

- Further growth (up 17%) in sandalwood product revenue, all of which dropped straight to the bottom line (up 72%) – illustrating the scalability of our processing facilities
- Further growth expected in H2 FY16 as the distillation of the majority of the 2015 harvest (acquired from the MIS growers in September) has only recently been completed
- Transformational growth expected in FY17 as the 2016 harvest will be 10x the 2015 harvest


#### Revenue (\$m)



#### Contribution (\$m)



## **Net Profit After Tax up by 23%**



## **Biological Asset Valuation**

- TFS's biological assets¹ increased to \$586m, up 16% on June 2015, reflecting larger directly owned estate, increased tree maturity and benefit of strengthening US
- No change to the valuation methodology used to value the plantations


| Key Assumptions                        | Assumption at 31 December 2015          | Comments  |
|--|---|---|
| Number of TFS owned trees <sup>1</sup> | 1,031,028                               | From annual inventory count in Q4 FY15  |
| Heartwood yield at harvest             | TFS projections                         | Based on extensive TFS and industry research Assessed as part of inventory count in Q4 FY15 |
| Oil content                            | 3.7%                                    | Based on research and actual results  |
| Oil price per kg                       | US\$2,800                               | Director assessment – not inflated FY15 oil sales: average of US\$4,385/ kg                 |
| FX                                     | US\$0.73c : AU\$1.00                    | Actual as at 31 December 2015   |
| Harvest and processing costs           | \$16,000 per kg and \$207 per kg of oil | Expected costs inflated at 3.0% pa  |
| Discount rate                          | 12-14%                                  | Rate applied is dependent on tree age   |

Note 1 - Excluding the external MIS growers' interests



| 14


### Cash Balance of \$52m



- Investment in land and plantations of \$25.0m in H1 FY16
- TFS's cash inflows from plantation sales are heavily weighted to H2
- Consistent with both FY14 and FY15, net cash generated by operating activities is expected to be positive for the full year (H1 result: \$22m outflow)


## Sale of Loan Book expected in H2

- Since 1998, TFS has offered vendor financing to plantation investors
  - Loans are secured by the Indian sandalwood plantation and are full recourse
  - Loans typically have a 7 year term and yield between 8% and 11%
- Periodically, TFS frees up capital by selling its loan book to third parties
  - In 2008, TFS sold a loan book to CBA, generating operating cash of \$21m
  - In 2013, TFS sold a loan book, generating operating cash of \$22m
- TFS expects to complete a loan book sale during H2 FY16
  - > At 31 December 2015, the loan book totalled \$38m





## A Vertically Integrated and Global Business



## **New Supply Agreements for TFS's Owned Harvest**

TFS owns 60% (c180 tonnes) of the 2016 harvest and this is now 100% committed to four different global buyers across four different markets, well ahead of harvest


- 1. China: First supply agreement signed with 150t of heartwood to be shipped from the 2016 harvest
  - > Price (for TFS's value added wood) is broadly equivalent to Galderma oil price of US\$4,500/ kg
  - Strong demand in China first large harvest this year will establish the authenticity of TFS's supply
- 2. India and Middle East: First supply agreement signed with 30t of heartwood to be shipped from the 2016 harvest
  - Pricing (for TFS processed billets) is broadly equivalent to Galderma oil price of US\$4,500/ kg
  - Counterparty is an existing customer which has acquired over AU\$30m of spicatum from TFS since 2008
- 3. Cosmetics: Commencement of supply of Indian sandalwood oil to Lush under a contract signed in 2008
  - Minimum of 1t of oil pa, first shipment expected in March 2016
  - Lush has over 900 stores in over 40 countries and has been buying TFS's spicatum oil since 2008
- 4. US pharmaceutical existing contract with Nestle owned Galderma to supply oil for the Benzac® range





## **Excellent Operational Performance**

- Excellent plantation performance during the wet season, especially in the Northern Territory during heavy rainfall in the Douglas Daly
- Significant scale added to our operational capacity
  - Second production line added to the Kununurra processing facility in advance of the 2016 harvest
  - Second seedling nursery built in Katherine, which will contribute to the 2016 plantings (see slide 34)
- Awarded Major Project Status by Northern Territory government which will increase government support for TFS projects in the state
- Oil for fine fragrance market included on approved product lists by two iconic global perfume houses



## **Promising Momentum in Plantation Sales**

- Continuing demand for plantation sales among institutional investors
  - > Sale of 214ha completed to Church Commissioners for England
- Strong momentum in sales to sophisticated investors (HNW)
  - Multiple sales signed in H1, compared to nil in both FY15 and FY14
  - > ATO approval already received, 3 months ahead of last year, providing for a far longer sales window
  - > As in prior years, plantation sales heavily weighted to the last quarter of the FY
- Support committed by one of Australia's leading independent financial planning groups (first time in 7 years) which significantly expands TFS's reach to further stimulate domestic sales
- Strong profit margin expansion in FY16 as establishment fees across all three investor groups (new institutions, sophisticated and retail) have been increased by over 10% on FY15
- Further profit margin expansion in FY16 as fewer sales will be made to our original institutional investors at contracted historical rates

## **Strong Growth in Benzac® Sales**

- Royalty income received from OTC product sales increased 3x in Q2 FY16
- 1.0 million units of the five OTC products were shipped in Q2 FY16 alone
- Strong consumer feedback with awards for Benzac® (distributed across the US by Galderma, wholly owned by Nestle) from ALLURE and HEALTH magazine
- New marketing campaign to commence in FY16





"The drugstore Acne Fighters

Dermatologists Swear By"



## **Accelerating Pharmaceutical Product Development**

- Phase 2 study commenced of an oral rinse to treat oral mucositis, a cancer-associated mouth condition
- Phase 2 trial commenced of a drug to treat molluscum contagiosum, a contagious skin infection that occurs predominantly in children
- Positive results from a study of pediatric patients with eczema with 82% of patients showing at least a 25% improvement – prescription drug trials expected to commence in CY2016

| Code       | Indication           | Formulation<br>Development | Phase I     | Phase II | Phase III | On Market |
|------------|----------------------|----------------------------|-------------|----------|-----------|-----------|
| VIR 001-00 | HPV (skin Warts)     |                            |             | <b></b>  | EOP2      |           |
| VIR 003-01 | Molluscum (MSV)      |                            |             | Q2FY16   |           |           |
| SAN 005-01 | Oral Mucositis       |                            | -           | Q2 FY16  |           |           |
| SAN 009-01 | Eczema / AD          |                            | <b></b>     | Q4 FY16  |           |           |
| SAN 022-00 | Pruritus (pediatric) |                            | <b>&gt;</b> | Q1 FY17  |           |           |
| SAN 021-00 | Psoriasis            |                            |             | Q1 FY17  |           |           |

## **Opportunity for Cost of Debt Savings**

- Senior secured notes of US\$200m (11% coupon) mature in July 2018
- TFS has been able to call the notes since July 2015:
  - > Call premium: 8% prior to July 2016
  - Call premium: 4% between July 2016 and July 2017
  - Call premium: 2% between July 2017 and July 2018
- Notes are traded through DTC and the last trade was in January at a price of \$104.25 indicating holders expect the notes to be refinanced in FY17
- TFS has appointed a leading global investment bank as its advisor and expects to refinance the notes once the call premium reduces to 4%, at which point the break-even coupon for the refinance is 9%
- Strong support evident from noteholders TFS's notes are narrowly held and thinly traded and one large global fund has acquired 100% of the issuances in the last two fiscal years



### Harvest Yields to Increase Tenfold in 2016

| Harvest Year   | 2014<br>Actual | 2015<br>Actual | 2016<br>Forecast |
|--|----------------|----------------|------------------|
| Area   | 100 ha         | 35 ha          | 104 ha           |
| Average age of tree                                      | 14 yrs         | 14.5 yrs       | 15 yrs           |
| Heartwood yield per tree (kg)                            | 3.1 kg         | 4.9 kg         | ≈9.7 kg          |
| Survival rate <sup>1</sup> (%)                           | 32%            | 38%            | ≈70%             |
| Heartwood yield (tonnes)                                 | 46 t           | 31 t           | >300 t           |
| TFS ownership at harvest (Direct and indirect ownership) | 38%            | 20%            | 60%              |
| Oil yield  | 3.3%           | 3.5%           | 3.7%             |


Results of enhanced forestry practices, including improved host trees and site selection

Note 1 - Plantations were established with 463 seedlings per ha in establishment years 1999 to 2001



| 26

### TFS's 2016 Harvest will Transform Cash Generation





### **Clear Priorities for 2016**

- Manage operational expansion to successfully harvest > 300 tonnes of heartwood
- Extend TFS's ownership of Indian sandalwood plantations and acquire the grower owned wood from the 2016 harvest
- Continue to develop cosmetic, Chinese wood, Indian wood and fine fragrance markets and finalise further long-term supply agreements
- Progress pharmaceutical product development finalise licence deals for further OTC products and advance trials for new products
- Introduce additional plantation investors, including new institutional investors and domestic high net worth and retail investors
- Consider refinance of the senior secured notes which mature in July 2018

**Reaffirmation of guidance for FY16:** 

Cash EBITDA: increase of 5% to 10% on FY15

New planting of around 1,500ha





### **Historical Financial Results**


| (\$m)                      | H1 2016 | H1 2015 | H1 2014 | H1 2013 |
|----------------------------|---------|---------|---------|---------|
| Total revenue <sup>1</sup> | 150.6   | 160.3   | 55.0    | 45.4    |
| Net profit after tax       | 67.4    | 55.0    | 3.2     | 4.8     |
| EBITDA                     | 107.0   | 92.6    | 16.6    | 15.9    |
| Basic earnings per share   | 19.9c   | 16.9c   | 1.2c    | 1.7c    |
| Cash operating revenue     | 60.7    | 51.7    | 27.2    | 18.4    |
| Cash EBITDA                | 8.6     | 6.7     | -9.0    | -11.1   |

Note 1 - Excluding the gain on the revaluation of the external MIS growers' interests

### **Reconciliation of PBT to Cash EBITDA**

| (\$m)   | H1 FY16 | H1 FY15 |
|---|---------|---------|
| Profit before income tax expense                                    | 88.4    | 78.3    |
| Depreciation and amortisation                                       | 4.7     | 4.1     |
| Finance costs and interest received                                 | 13.9    | 10.2    |
| EBITDA  | 107.0   | 92.6    |
| Biological asset fair value movement (including FX gain)            | -74.5   | -89.6   |
| Revenue from deferred fees  | -15.4   | -19.0   |
| Unrealised FX loss on senior secured notes                          | 11.6    | 23.6    |
| Share of net profit of associates                                   | -6.6    | -0.9    |
| Gain on acquisition of controlling interest in Santalis and Viroxis | -17.2   | -       |
| Fair value movement in value of contingent consideration            | 3.7     | -       |
| Cash EBITDA   | 8.6     | 6.7     |

## **Accounting for Acquisition of Santalis and Viroxis**



• Profit of \$16.8m recorded in P&L arising from the deemed disposal of 50% in Santalis already owned at acquisition



